Previous business/academic article Next business/academic article
Business Articles Awards > Intellectual Property

Pharma Giants in Antitrust Pricing Lawsuit over Biosimilars

Steven J. Cernak, George Yu, Schiff Hardin Alert, 09.26.2017

See Steven J. Cernak's resume See George Yu's resume

Click here to read the full article online

Pfizer sued Johnson & Johnson (J&J) in federal court in Pennsylvania last week, alleging anticompetitive discounts and other actions to prevent competition with J&J’s biologic Remicade. The complaint illustrates the hurdles to successfully bringing a biosimilar to market, despite the Biologics Price Competition and Innovation Act (BPCIA). The case also will provide another opportunity for courts to evaluate the antitrust implications of loyalty discounts and bundling.

Download our brochure